Recursion Pharmaceuticals (NASDAQ: RXRX) Declines 7% Following Phase 2 Data of REC-994Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE